Assessing a compound's activity, not just its structure, could accelerate drug discovery

(NIH/National Center for Advancing Translational Sciences (NCATS)) Assessing a drug compound by its activity, not simply its structure, is a new approach that could speed the search for COVID-19 therapies and reveal more potential therapies for other diseases. This action-based focus -- called biological activity-based modeling (BABM) -- forms the core of a new approach developed by National Center for Advancing Translational Sciences (NCATS) researchers and others.